

Penn's Abramson Cancer Center and
Children's Hospital of Philadelphia present

CAR-T AND THE RISE OF CELLICON VALLEY

Thursday, May 9, 2019 | 1:00 pm to 9:30 pm

Friday, May 10, 2019 | 8:00 am to 5:00 pm

REGISTER AT PENNMEDICINE.ORG/CART2019

Irvine Auditorium and Perelman Quadrangle // 3401/3417 Spruce St., Philadelphia, PA 19104

The University of Pennsylvania Museum of Archaeology and Anthropology // 3260 South St., Philadelphia, PA 19104

CAR-T AND THE RISE OF CELLICON VALLEY

PHILADELPHIA

THURSDAY, MAY 9, 2019 — KEYNOTE ADDRESS
FRIDAY, MAY 10, 2019 — PRESENTATIONS:

CURRENT APPLICATION OF CAR T CELLS

Moderator: David L Porter, MD // Penn Medicine

Carl H June, MD // Penn Medicine

David Maloney, MD, PhD // Fred Hutchinson Cancer
Research Center/Seattle Cancer Care Alliance/
University of Washington

James N Kochenderfer, MD // National Cancer
Institute

TOXICITY MANAGEMENT

Moderator: Stephan A Grupp, MD, PhD // Children's
Hospital of Philadelphia

Shannon L Maude, MD, PhD // Children's Hospital of
Philadelphia

Sattva S Neelapu, MD // The University of Texas MD
Anderson Cancer Center

Renier J Brentjens, MD, PhD // Memorial Sloan
Kettering Cancer Center

OVERCOMING RESISTANCE/NOVEL CAR STRATEGIES

Moderator: Carl H June, MD // Penn Medicine

Megan S Lim, MD, PhD // Penn Medicine

Travis Young, PhD // California Institute for
Biomedical Research

Martin Pule, MB BCh, MRCP // University College
London

GENE DELIVERY AND EDITING FOR BETTER CARs

Moderator: Michael C Milone, MD, PhD // Penn
Medicine

Alexander Marson, MD, PhD // University of
California, San Francisco

Bruce McCreedy, PhD // Precision Biosciences

David J Rawlings, MD // Seattle Children's Research
Institute

NEW TARGETS AND TECHNOLOGIES ALLOGENEIC AND TREG CAR Ts

Moderator: Marco Ruella, MD // Penn Medicine

Christine Brown, PhD // City of Hope

Carl H June, MD // Penn Medicine

Darrell J Irvine, PhD // Massachusetts Institute of
Technology

ALLOGENEIC CAR Ts AND NKs: THE FUTURE IS NOW?

Moderator: Stephen J Schuster, MD // Penn
Medicine

Katy Rezvani, MD, PhD // The University of Texas MD
Anderson Cancer Center

David Chang MD, PhD // Allogene Therapeutics

David Gilham, PhD // Celyad

GLOBALIZATION OF CAR T CELL THERAPIES


Moderator: Usman "Oz" Azam, MD // Tmunity

Panel To Be Announced

Plus 10 Breakout sessions. Topics include: cell manufacturing; gene therapy and regulatory considerations; unconventional CARs; cell manufacturing analytics; financial implications; unconventional CARs; Pediatric - SCT, GVHD, antiviral therapies, CAR T in special populations and gene edited SCT for SS and thalassemia; nursing care of adult and pediatric patients.

Arrive early on May 9 and tour Center for Advanced Cellular Therapeutics.


Activity Directors



Carl H June, MD




Stephan A Grupp, MD, PhD



Bruce L Levine, PhD



David L Porter, MD



OVERVIEW

CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to disease within the field of cellular therapy and transplant. The recent approval of chimeric antigen receptor (CAR) T cells offers even patients with highly chemo-refractory hematologic malignancies additional treatment options. World experts in CAR T-cellular therapy and hematopoietic stem cell transplantation (HSCT) have been assembled to discuss the development and implementation of this therapy and to weigh in on current applications, best practices, novel strategies and future developments for CAR T cells.

LEARNING OBJECTIVES

Upon completion of this course, participants should be able to:

- Identify current application of CAR T-cell therapy including: accurate patient selection, manufacture and treatment administration
- Implement guidelines for patient management of toxicities of CAR T-cell therapies including cytokine-release syndrome
- List factors in overcoming resistance with novel CAR strategies
- Describe gene delivery and editing for CARs
- Identify the latest targets and technologies for CARs
- Identify the current status of globalization of CAR T-cell therapies and identify principles in ethics of patient access
- Describe current approaches in treatment and supportive care for hematopoietic stem cell transplantation (HSCT) in pediatric patients with nonmalignant conditions
- Identify the latest evidence based standards in nursing care resulting from the recent advances in cell therapy and transplant

WHO SHOULD ATTEND

These activities are intended for both adult and pediatric hematologist-oncologists, medical oncologists, hematologists, hematopathologists, immunologists, immunobiologists, transfusion medicine, researchers and other healthcare professionals interested in the latest advances in the use

of CAR T-cell therapy. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of adult and pediatric patients with cellular therapies are also invited to attend.



Penn Medicine

Abramson Cancer Center

3600 Civic Center Boulevard
5th Floor- Suite 500
Philadelphia, PA 19104

Non-Profit Org.
U.S. Postage
PAID
Permit No. 2563
Phila, PA 19176

Penn's Abramson Cancer Center and
Children's Hospital of Philadelphia present

CAR-T AND THE RISE OF CELLICON VALLEY

Thursday, May 9, 2019 | 1:00 pm to 9:30 pm

Friday, May 10, 2019 | 8:00 am to 5:00 pm

REGISTER AT PennMedicine.org/CART2019

